EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
2024: research highlights of last year and the year ahead
With the announcement of some very encouraging results from completed clinical trials last year, and a number of promising new projects focused on disease modification – the outlook for 2024 is looking good!
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.
Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.
A review of our 2023 preclinical projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further tested in a clinical trial.
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.